When is aprocitentan expected to be officially launched?

Aprocitentan (Aprocitentan) is a new oral drug mainly used to treat high blood pressure, especially in patients who do not respond well to traditional antihypertensive drugs. This drug is unique in that it lowers blood pressure by blocking endothelinA receptors. Due to its targeted mechanism of action, aprecitentan can effectively control high blood pressure while reducing the side effects that traditional drugs may cause. However, although aprexitentan has been marketed in other countries, it has not yet been officially approved for marketing in China.

There is currently no official information on the launch date of apremicitentan in China. Normally, the process from approval to official marketing of a drug may require multiple approval procedures, including review of clinical data, approval of drug production, and establishment of sales channels. In view of the fierce competition in the domestic hypertension market and the therapeutic potential of the drug, it is expected that aprexitentan may officially enter the Chinese market in the next one to two years. The marketing of drugs also needs to be approved by the National Medical Products Administration of China (NMPA), and the approval time will be affected by a variety of factors.

For patients who are in urgent need of aprexitentan, although the drug has not yet been launched in China, it can be purchased through regular overseas channels. Patients can choose to purchase legally through some reliable international pharmaceutical platforms or from other countries. Especially in Laos, the generic version of Apresitentan has been officially launched, and the price is relatively affordable, with each box selling for about a few hundred yuan. Because generic drugs are similar in ingredients and effects to the brand-name drugs, they have become an economical choice for many patients, especially while waiting for the drug to be officially launched.

To sum up, there is no clear date for the launch of aprecitentan in China, and it is expected to take one to two years. While patients are waiting for the drug to be launched, they can choose to purchase generic drugs through overseas channels. As the domestic demand for hypertension treatment continues to increase, aprecitentan, as a new drug with great potential, is expected to provide effective treatment options for more patients in the future.

Reference materials:https://go.drugbank.com/drugs/DB15059